Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel

International Journal of Cancer

Volumn 121, Issue 2, 2007, Pages 407-415

  Gril, Brunilde ^a,b,c,e   Vidal, Michel ^a,b,c   Assayag, Franck ^d   Poupon, Marie France ^d   Liu, Wang Qing ^a,b,c   Garbay, Christiane ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c CNRS   (France)

^d INSTITUT CURIE   (France)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Grb2; HER2; SH3 domain; Xenograft cancer

Indexed keywords

DOCETAXEL; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDIMER C; PROTEIN KINASE B; PROTEIN SH3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MOUSE; NONHUMAN; ONCOGENE NEU; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GRB2 ADAPTOR PROTEIN; HUMANS; LIGANDS; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASMS; OLIGOPEPTIDES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; TAXOIDS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250366212     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22674     Document Type: Article

References (36)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
2. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, and Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
4. Foster CS, Gosden CM, Ke Y. HER2/neu expression in cancer: the pathologist as diagnostician or prophet? Hum Pathol 2003;34: 635-8.
5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
6. Pusztai L, Esteva FJ. Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest 2006;24:187-91.
7. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3: 269-80.
8. Lowenstein EJ, Daty, RJ, Batzer AG, Li W, Margolis B, Lammers R. Ullrich A, Skolnik EY, Bar-Sagi D, Schlessinger J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992;70:431-42.
9. Chardin P, Cussac D, Maignan S, Ducruix A. The Grb2 adaptor. FEBS Lett 1995;369:47-51.
10. Buday L, Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor. Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 1993;73:611-20.
11. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 1993;363:83-5.
12. Daly RJ, Binder MD, Sutherland RL. Overexpression of the Grb2 gene in human breasi cancer cell lines. Oncogene 1994;9:2723-7.
13. Verbeek BS, Adriaansen-Slot SS, Rijksen G, Vroom TM. Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J Pathol 1997;183:195-203.
14. Cheng AM, Saxton TM, Sakai R, Kulkarni S, Mbamalu G, Vogel W, Tortorice CG, Cardiff RD, Cross JC, Muller WJ, Pawson T. Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell 1998;95:793-803.
15. Xie Y, Pendergast AM, Hung MC. Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. J Biol Chem 1995;270: 30717-24.
16. Vidal M, Liu WQ, Lenoir C, Salzmann J, Gresh N, Garbay C. Design of peptoid analogue dimers and measure of their affinity for Grb2 SH3 domains. Biochemistry 2004;43:7336-44.
17. Garbay C, Liu WQ, Vidal M, Roques BP. Inhibitors of Ras signal transduction as antitumor agents. Biochem Pharmacol 2000;60: 1165-9.
18. Cussac D, Vidal M, Leprince C, Liu WQ, Cornille F, Tiraboschi G, Roques BP, Garbay C. A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays anti-proliferative activity. FASEB J 1999;13:31-8.
19. de Pinieux G, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Goncalves R, Dutrillaux AM, Nemati F, Outlard S, Lidereau R, Broqua P, Junien JL, Dutrillaux B, et al. Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol 2001;159:753-64.
20. Lewitzky M, Harkiolaki M, Domart MC, Jones EY, Feller SM. Mona/ Gads SH3C binding to hematopoietic progenitor kinase 1 (HPK1) combines an alypical SH3 binding motif, R/KXXK, with a classical PXXP motif embedded in a polyproline type II (PPII) helix. J Biol Chem 2004;279:28724-32.
21. Guyot B, Mouchiroud G. Characterization of promoter elements directing Mona/Gads molecular adapter expression in T and myelomonocytic cells: involvement of the AML-1 transcription factor. J Leukoc Biol 2003;73:263-72.
22. Riese DJ, II. Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41-8.
23. Oudard S, Legrier ME, Boye K, Bras-Goncalves R, De Pinieux G, De Cremoux P, Poupon MF. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169:1729-34.
24. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000;19:6594-9.
25. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-16.
26. Gay B, Suarez S, Caravatti G, Furet P, Meyer T. Schoepfer J. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int J Cancer 1999;83:235-41.
27. Ramaswamy B, Puhalla S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs. Today (Barc) 2006;42:265-79.
28. Wolfson M, Yang CP, Horwitz SB. Taxol induces tyrosine phosphorylation of Shc and its association with Grb2 in murine RAW 264.7 cells. Int J Cancer 1997;70:248-52.
29. Lim SJ, Lopez-Berestein G, Hung MC, Lupu R, Tari AM. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene 2000;19:6271-6.
30. Mano MS, Awada A, Minisini A, Durbecq V, Di Leo A, Piccart M. Exquisite antitumor response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and P13K-Akt pathways activation. Breast 2004;13:347-9.
31. Kang SU, Shi ZD, Worthy KM, Bindu LK, Dharmawardana PC, Choyke SJ, Bottaro DP, Fisher RJ, Burke TR, Jr. Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform. J Med Chem 2005;48:3945-8.
32. Kang SU, Worthy KM, Bindu LK, Zhang M, Yang D, Fisher RJ, Burke TR, Jr. Design and synthesis of 4-(α-hydroxymalonyl)phenylalanine as a new phosphotyrosyl mimetic and its use in growth factor receptor bound 2 src-homology 2 (Grb2 SH2) domain-binding peptides. J Med Chem 2005;48:5369-72.
33. Lee KY, Hyeok Yoon JH, Kim M, Roll S, Lee YS, Seong BL, Kim K. A dipalmitoyl peptide that binds SH3 domain, disturbs intracellular signal transduction, and inhibits tumor growth in vivo. Biochem Biophys Res Commun 2002;296:434-42.
34. Kim HK, Jeong MJ, Kong MY, Han MY, Son KM, Kim HM, Hong SH, Kwon BM. Inhibition of Shc/Grb2 protein-protein interaction suppresses growth of B104-1-1 tumors xenografted in nude mice. Life Sci 2005;78:321-8.
35. Arkin M. Protein-protein interactions and cancer: small molecules going in for the kill. Curr Opin Chem Biol 2005;9:317-24.
36. Feller SM, Lewitzky M. Potential disease targets for drugs that disrupt protein - protein interactions of Grb2 and Crk family adaptors. Curr Pharm Des 2006;12:529-48.